Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.
Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.
